Niamh Moriarty

Niamh Moriarty

Auto-generated profile, based on publicly available information

Niamh Moriarty

The Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2022 in Cell Stem Cell
Verified
Journal Article
Closed access
NMNiamh Moriarty
Niamh Moriarty
CGCarlos W. Gantner
Carlos W. Gantner
CHCameron P.J. Hunt
Cameron P.J. Hunt
CECharlotte M. Ermine
Charlotte M. Ermine
SFStefano Frausin
Stefano Frausin
LTLachlan H. Thompson
Lachlan H. Thompson

16 November 2018 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
KBK F Bruggeman
K F Bruggeman
NMN Moriarty
N Moriarty
EDEilís Dowd
Eilís Dowd
David NisbetDavid Nisbet
David Nisbet
CPClare L. Parish
Clare L. Parish

23 August 2021 in Neuronal Signaling
Verified
Journal Article
Open access
PDF file
SCSílvia Cabré
Sílvia Cabré
VAVerónica Alamilla
Verónica Alamilla
NMNiamh Moriarty
Niamh Moriarty
Abhay PanditAbhay Pandit
Abhay Pandit
EDEilís Dowd
Eilís Dowd
In cell replacement approaches for Parkinson’s disease, the intracerebral implantation of dopamine neuron-rich grafts generates a neuroinflammatory response to the grafted cells that contributes to its varied outcome. Thus, the aim of the present study was to fabricate an anti-inflammatory cytokine-eluting collagen hydrogel capable of delivering interleukin (IL)-10 to the brain for reduction of the neuroinflammatory response to intracerebral cellular grafts. In vitro assessment revealed that cross-linker concentration affected the microstructure and gelation kinetics of the hydrogels and their IL-10 elution kinetics, but not their cytocompatibility or the functionality of the eluted IL-10. In vivo evaluation revealed that the hydrogels were capable of delivering and retaining IL-10 in the rat striatum, and reducing the neuroinflammatory (microglial) response to hydrogel-encapsulated grafts. In conclusion, IL-10-eluting collagen hydrogels may have beneficial anti-inflammatory effects in the context of cellular brain repair therapies for Parkinson’s disease and should be investigated further.

10 December 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
CGCarlos W Gantner
Carlos W Gantner
ILIsabelle R de Luzy
Isabelle R de Luzy
JKJessica A Kauhausen
Jessica A Kauhausen
NMNiamh Moriarty
Niamh Moriarty
JNJonathan C Niclis
Jonathan C Niclis
CPClare L. Parish
Clare L. Parish
The derivation of neurotransmitter and region-specific neuronal populations from human pluripotent stem cells (PSC) provides impetus for advancing cell therapies into the clinic. At the forefront is our ability to generate ventral midbrain (VM) dopaminergic (DA) progenitors, suitable for transplantation in Parkinson’s disease (PD). Pre-clinical studies, however, have highlighted the low proportion of DA neurons within these grafts and their inferior plasticity by comparison to human fetal donor transplants. Here we sought to examine whether modification of the host environment, through viral delivery of a developmentally critical molecule, glial cell line-derived neurotrophic factor (GDNF), could improve graft survival, integration and function in Parkinsonian rodents. Utilising LMX1A- and PITX3-GFP hPSC reporter lines, we tracked the response of DA progenitors implanted into either a GDNF-rich environment, or in a second group, after a 3-week delay in onset of exposure. We found that early exposure of the graft to GDNF promoted survival of DA and non-DA cells, leading to enhanced motor recovery in PD rats. Delayed overexpression of intrastriatal GDNF also promoted motor recovery in transplanted rats, through alternate selective mechanisms including enhanced A9/A10 specification, increased DA graft plasticity, greater activation of striatal neurons and elevated DA metabolism. Lastly, transcriptional profiling of the grafts highlighted novel genes underpinning these changes. Collectively these results demonstrate the potential of targeted neurotrophic gene therapy strategies to improve human PSC graft outcomes.

2 June 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
CPChiara Pavan
Chiara Pavan
KLKristian Honnens de Lichtenberg
Kristian Honnens de Lichtenberg
CGCarlos William Gantner
Carlos William Gantner
SFStefano Frausin
Stefano Frausin
JCJoseph Chen
Joseph Chen
CPClare L. Parish
Clare L. Parish
SUMMARY: The survival of transplanted ventral midbrain (vm) dopaminergic neurons (DAn) and their innervation of host striatal tissue are crucial for ameliorating motor symptoms in Parkinson’s disease (PD). However, human pluripotent stem cells (hPSC) show inferior axonal plasticity compared to fetal donor tissue. While modulation of the host environment with trophic cues, such as glial cell-derived neurotrophic factor (GDNF), can improve graft outcomes, these cues lack specificity for DAn, resulting in plasticity of other neurons within the graft. Using single nuclei RNA sequencing, we identified axonal guidance pathways (Semaphorin, Netrin and Wnt) that were preferentially activated in DAn within the graft. Overexpression of Semaphorin3A/SEMA3A, Netrin1/NTN1 or WNT5A in the striatum of Parkinsonian mice following vm DA progenitor transplantation promoted A9-DA specification and selectively increased DA innervation of the host striatum, without off-target extrastriatal DA innervation observed in response to GDNF. In Parkinsonian rats, NTN1 overexpression promoted graft-induced motor recovery, selective DA plasticity and activation of postsynaptic striatal neurons without evidence of non-DAn plasticity. Further, snRNA-sequencing of NTN1 or GDNF-treated grafts confirmed the upregulation of DA-specific plasticity by NTN1, while GDNF promoted plasticity in both DA and non-DAn. These findings highlight the capacity to improve on-target integration of hPSC-derived DAn in grafts by selectively targeting DA-specific plasticity. Taken together, these results demonstrate the utility of DA-specific cues to promote functional recovery, improve graft predictability, and limit off-target innervation.

Verified
Dataset
Open access
CHCameron Hunt
Cameron Hunt
VPVanessa Penna
Vanessa Penna
CGCarlos Gantner
Carlos Gantner
NMNiamh Moriarty
Niamh Moriarty
YWYi Wang
Yi Wang
CPClare L. Parish
Clare L. Parish
All data sets corresponding to figure published in Advanced Functional Materials "Tissue programmed hydrogels functionalized with GDNF improve human neural grafts in Parkinson’s Disease".